Given the role that CD4+ T cells play in orchestrating immune responses, if feasible, restoration of exhausted CD4+ T-cell function by ICB may contribute significant clinical benefit in patients with tumors, either by improving direct CD4+ T-cell anti-tumor activity or increasing the helper functions of these cells. The gene discussed is CD4; the disease is neoplasm.